On Wednesday 06/25/2025 the closing price of the Precigen share was $1.43 on BTT.
Compared to the opening price on Wednesday 06/25/2025 on BTT of $1.50, this is a drop of 5.26%.
Precigen's market capitalization is $355.78 M by 295.18 M shares outstanding.
Is Precigen stock a Buy, Sell or Hold?
Precigen stock has received a consensus rating of buy. The average rating score is and is based on 11 buy ratings, 0 hold ratings, and 0 sell ratings.
What was the 52-week low for Precigen stock?
The low in the last 52 weeks of Precigen stock was 0.65. According to the current price, Precigen is 217.89% away from the 52-week low.
What was the 52-week high for Precigen stock?
The high in the last 52 weeks of Precigen stock was 2.17. According to the current price, Precigen is 65.82% away from the 52-week high.
What are analysts forecasts for Precigen stock?
The 11 analysts offering price forecasts for Precigen have a median target of 7.91, with a high estimate of 14.00 and a low estimate of 6.00. The median estimate represents a 18.02 difference from the last price of 1.43.
Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the following segments: Biopharmaceuticals, Exemplar, and Trans Ova. The Biopharmaceuticals segment is involved in advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. It also engages in pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics. The Exemplar segment is focused on developing research models and services for healthcare research applications. The Trans Ova segment provides bovine reproductive technologies. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.
Moody’s Daily Credit Risk Score
Risk
Low
Medium
High
8
Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s
balance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of credit
risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into
account day-to-day movements in market value compared to a company’s liability structure.
